MAP2K7 and breast cancer: However, patients at high risk of BC are not susceptible to AP.24534 (Ponatinib), AS601245 (JNK inhibitor), AZ628 (Raf inhibitor), AZD.2281 (Olaparib), AZD6244 (Selumetinib), CI.1040 (Mek inhibitor), Cytarabine, GDC.0449 (Vismodegib), Gemcitabine, JNK.9L, Lenalidomide, Nilotinib, PD.173074 (FGFR inhibitor), PD.0332991 (Palbociclib), PF.4708671 (S6 Kinase inhibitor), Pyrimethamine, Roscovitine (CDK inhibitor), SB590885 (B-Raf inhibitor) and Temsirolimus may have resistance.